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Toxoplasma gondii tachyzoite-
extract acts as a potent 
immunomodulator against 
allergic sensitization and airway 
inflammation
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Roman Peschke3, Anja Joachim3, Ursula Wiedermann1 & Irma Schabussova1
Epidemiological and experimental studies have shown an inverse relationship between infections 
with certain parasites and a reduced incidence of allergic diseases. We and others have shown that 
infection with Toxoplasma gondii prevents the development of allergy in mice. To establish whether this 
beneficial effect could be recapitulated by soluble products of this parasite, we tested an extract derived 
from T. gondii tachyzoites. Immunization of BALB/c mice with tachyzoites lysate antigen (TLA) elicited 
mixed Th1/Th2 responses. When TLA was applied together with the sensitizing ovalbumin (OVA), the 
development of allergic airway inflammation was reduced, with decreased airway hyperresponsiveness 
associated with reduced peribronchial and perivascular cellular infiltration, reduced production of 
OVA-specific Th2 cytokines in lungs and spleens and reduced levels of serum OVA-specific IgG1 as well 
as IgE-dependent basophil degranulation. Of note, TLA retained its immunomodulatory properties, 
inducing high levels of IL-6, TNFα, IL-10 and IL-12p70 in bone marrow-derived dendritic cells after heat-
inactivation or proteinase K-treatment for disruption of proteins, but not after sodium metaperiodate-
treatment that degrades carbohydrate structures, suggesting that carbohydrates may play a role in 
immunomodulatory properties of TLA. Here we show that extracts derived from parasites may replicate 
the benefits of parasitic infection, offering new therapies for immune-mediated disorders.
The prevalence of allergic, inflammatory and autoimmune diseases has been increasing in industrialized coun-
tries in the last few decades1. This trend has been correlated with lifestyle changes, such as increase in hygiene 
measures, the wide use of antibiotics, vaccinations, as well as reduced exposure to different infectious agents, such 
as bacteria, protozoa and helminths2–4. This correlation has received significant interest, resulting in formulation 
of the hygiene hypothesis5 and subsequently, in many epidemiological and experimental studies. For example, 
infection with helminth parasites, like Heligmosomoides polygyrus6, Litomosoides sigmodontis7 or Trichinella spi-
ralis8 have been shown to reduce allergic airway inflammation in several murine models. Importantly, beneficial 
effects of infections with certain helminths on chronic inflammatory conditions have also been observed in clin-
ical trials9–14. However, the introduction of potentially pathogenic parasites as a treatment strategy raises several 
concerns regarding the safety of such an application. Therefore, there is an interest in identifying parasite-derived 
molecules to treat immune-mediated diseases or to use them as adjuvants with immunomodulatory effects in 
future allergy vaccines. In this respect, parasitic products were already tested and their beneficial effects on exper-
imental allergy have been shown15,16.
Toxoplasma gondii is an obligatory intracellular protozoan parasite with wide range of hosts, including humans 
and with approximately 30% prevalence worldwide17. The infection with T. gondii develops upon ingestion of 
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oocysts, the parasitic stage shed in feces of cats that contaminate soil, food or water, or through the consumption 
of raw or undercooked meat containing tissue cysts18. Once ingested, the oocysts rupture in the gut and release 
sporozoites into the lumen. Sporozoites infect enterocytes and differentiate into tachyzoites, which are highly 
proliferative, mobile, and rapidly disseminate throughout the body, inducing an acute immune response17,19. 
Although acute infection is usually asymptomatic in immunocompetent host, in rare occasions it may result in 
fever and lymphadenopathy followed by chronic infection. In immunosuppressed patients and in fetuses it can 
cause severe disease, with frequent manifestations in the eye or the central nervous system18,20. Interestingly, epi-
demiological studies suggested inverse associations between T. gondii seropositivity and allergic sensitization21–23. 
Along these lines, we and others have previously shown that experimental infection with T. gondii suppressed 
allergic airway inflammation in mouse models24,25. Furthermore, we have shown that not only the infection with 
live T. gondii, but also the treatment with crude extract derived from T. gondii oocysts (OLA) can reduce the 
development of allergic responses in a mouse model of birch pollen allergy26. However, the collection of T. gondii 
oocysts for OLA preparation is linked with several obstacles, such as necessity of passage of the parasite through 
the feline host, low parasite yield or possible contamination with bacterial components, especially endotoxin, or 
host-derived material. On the contrary, tachyzoites can be cultured in vitro in Vero cells, allowing the collection 
of T. gondii compounds in high quantity without the risk of contamination. Most importantly, there is no loss of 
immunogenic properties through continuous passages27–29. This culturing method thus offers several biological, 
ethical and economic benefits over protocols for isolation of other developmental stages, such as oocysts.
The aim of this study was to evaluate immunomodulatory properties of tachyzoites lysate antigen (TLA) and 
to establish whether experimental allergy could be prevented by this extract. TLA is a mixture of proteins and 
carbohydrates30–32 and the identification of specific suppressive factors in TLA may lead to development of novel 
therapeutic applications to control immune-mediated inflammatory diseases.
Results
TLA triggers the production of pro- and anti-inflammatory cytokines in naïve splenocytes in 
vitro. To determine the immunostimulatory capacity of TLA in vitro, splenocytes from naïve BALB/c mice 
were cultured for three days with 5 and 10 µg TLA. In comparison to cells stimulated with medium only, TLA-
stimulated cells induced significant levels of pro-inflammatory cytokines such as IL-6, IFNγ, TNFα as well as the 
anti-inflammatory cytokine IL-10 (Fig. 1).
Immunization with TLA elicits mixed Th1/Th2 humoral and cellular immune responses. To test 
humoral and cellular immune responses induced by TLA in vivo, BALB/c mice were immunized with TLA in 
alum or sham-treated with PBS in alum (Fig. 2a). Levels of TLA-specific antibodies in serum were measured on 
day 0 and 21. TLA-immunization led to significant production of TLA-specific IgG2a (Th1-associated isotype), as 
well as TLA-specific IgG1 (Th2-associated isotype) when compared to levels in pre-immune serum collected on 
day 0 and to levels in serum of sham-treated mice collected on day 21 (Fig. 2b). However, TLA-specific levels of 
another Th2-associated antibody, IgE, remained unchanged (measured OD for the TLA group was 0.17 ± 0.005 
and 0.18 ± 0.007 on day 0 and 21, respectively; P = 0.2481). Restimulation of spleen cells from TLA-immunized 
mice with TLA ex vivo led to increased levels of Th1-related cytokines IL-6, IFNγ and TNFα, as well as Th2 
cytokines IL-5 and IL-4 and regulatory IL-10 compared to cultures incubated with medium only. Similarly, stimu-
lation of splenocytes from TLA-immunized mice with TLA induced higher production of most of these cytokines 
in comparison to levels detected in spleen cell cultures from TLA-stimulated sham-treated mice (Fig. 2c).
TLA reduces AHR and prevents allergic inflammation in lungs. To investigate whether TLA can mod-
ulate allergic lung inflammation, we used a mouse model of systemic sensitization and intranasal challenge with 
OVA. Mice were immunized i.p. with alum-adjuvanted OVA in the presence (TLA + OVA/OVA group) or absence 
(OVA/OVA group) of TLA. Control groups were immunized with PBS (PBS/PBS group) or TLA (TLA/PBS group) 
in alum only and challenged with PBS as indicated in Fig. 3a. A dose-dependent increase in AHR to methacholine, 
a nonspecific bronchoconstrictor, is one of the characteristics of allergic asthma33. As expected, intranasal challenge 
with OVA led to increased AHR in OVA/OVA mice in comparison to PBS/PBS mice, as demonstrated by increased 
levels of methacholine-induced PenH (Fig. 3b). Furthermore, OVA challenge led to increased numbers of eosino-
phils in BALF and increased numbers of inflammatory cells and goblet cell hyperplasia in lungs in comparison to 
PBS/PBS mice (Fig. 3c–f). Intraperitoneal treatment of sensitized mice with TLA (TLA + OVA/OVA) significantly 
suppressed the development of AHR compared to OVA/OVA mice, resulting in PenH values similar to those seen 
in negative controls (Fig. 3b). Reduced AHR was associated with reduced eosinophils in BALF (Fig. 3c,d) and 
reduced infiltration of inflammatory cells into perivascular and peribronchiolar connective tissues (Fig. 3e; H&E 
staining). In parallel, TLA reduced goblet cell hyperplasia in lungs in comparison to OVA/OVA group (Fig. 3e; PAS 
staining). Immunization with TLA without OVA-sensitization and challenge (TLA/PBS) led to a similar outcome 
as sham-treatment (PBS/PBS) (Fig. 3b–f). Stimulation of lung cell cultures of OVA/OVA mice with OVA ex vivo led 
to high levels of IL-5, IL-4, IL-13, and IL-10 (Fig. 4). Lung cells of TLA + OVA/OVA mice exhibited reduced IL-5 
and IL-13, but increased levels of IFNγ in response to OVA (Fig. 4). Levels of IL-4 and IL-10 were reduced as well, 
but the difference did not reach statistical significance (Fig. 4).
TLA inhibits the development of Th2-type allergen-specific immune responses. In order to 
determine whether TLA could affect also the induction of allergen-specific humoral responses, we measured the 
levels of OVA-specific antibodies in serum. Samples were collected before sensitization (d 0) and after the sensiti-
zation and challenge on the sacrifice (d 25). As shown in Fig. 5a, mice sensitized and challenged with OVA (OVA/
OVA) exhibited increased levels of specific antibodies in sera collected on day 25 in comparison to levels in sam-
ples collected on day 0 (Fig. 5a). Although TLA-treatment in TLA + OVA/OVA group had no impact on the levels 
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of OVA-specific IgG2a (Fig. 5a), it markedly reduced levels of IgG1 as well as the IgE-dependent basophil degran-
ulation in the RBL assay (Fig. 5a). Furthermore, we aimed to exclude the possibility that certain soluble factors in 
sera of TLA + OVA/OVA mice interfere with the basophil degranulation in RBL assay. Therefore, RBL cells were 
preincubated with sera of TLA-immunized mice prior to incubation with sera of OVA-sensitized. The results 
indicate, that reduced levels of β-hexosaminidase in cultures treated with sera from TLA + OVA/OVA mice in 
comparison to levels obtained by incubation with sera from OVA/OVA mice is not caused by soluble factors pres-
ent in the sera of TLA-treated mice (Supplementary Fig. S1). The levels of OVA-specific antibodies in TLA/PBS 
were comparable with levels detected in PBS/PBS mice (Fig. 5a). Additionally, restimulation of spleen cell cul-
tures of TLA + OVA/OVA mice with OVA led to reduced production of Th2 cytokines IL-5 and IL-4, as well as of 
regulatory IL-10 in comparison to cultures of OVA/OVA mice. However, TLA-treatment of OVA-sensitized mice 
led to increased levels of IFNγ in TLA + OVA/OVA mice in comparison to mice in OVA/OVA group (Fig. 5b). 
In these experiments, PBS/PBS and OVA/OVA groups were evaluated as negative and positive controls, respec-
tively, to determine the effect of co-application of TLA and sensitizing allergen on the development of airway 
inflammation. Comparison to PBS/PBS group enables to resolve the potential consequence of TLA-treatment 
on immunological parameters in the lungs. However, in order to determine the baseline for measurement of 
TLA-induced effects (interference during sensitization) on allergen-induced airway inflammation, additionally, 
we measured humoral and cellular immune responses in non-sensitized and OVA-challenged mice and compared 
Figure 1. Cytokine production of TLA-stimulated splenocytes. Splenocytes from naïve mice were cultured 
with media only (Med), 10 and 5 µg/ml TLA for 72 h. Ultra-pure lipopolysaccharide from E. coli (LPS; 1 µg/
ml) and Pam3CSK4 (Pam3; 1 µg/ml) were used as positive controls. Levels of cytokines in culture supernatants 
were determined by ELISA. Three replicate cultures with cells from individual mice were measured. All data are 
representative of at least three independent experiments performed using different batches of TLA. Error bars 
show mean ± SEM. Results of Student´s t test: **P < 0.01, ***P < 0.001.
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them to PBS/PBS and OVA/OVA groups. Here, we could clearly show that non-sensitized OVA-challenged mice 
exhibit comparable levels of AHR, eosinophils in BAL, inflammatory infiltrates, Th2 cytokines in the lungs and 
OVA-specific antibodies in serum, when compared to PBS/PBS mice. Furthermore, all measured parameters were 
markedly different when compared to levels observed in OVA/OVA mice (Supplementary Fig. S2-4).
Immunostimulatory potential of TLA is not impaired by heat-inactivation. To investigate whether 
TLA-components responsible for immunomodulation are heat-stable, TLA was heated at 96 °C for 15 min to 
denature proteins (TLA H) and tested in vitro and in vivo. Stimulation of splenocytes from naïve mice with TLA 
or TLA H led to comparable production of IL-6, TNFα and IL-10. TLA H was more potent in the induction of 
IFNγ in comparison to native TLA (Fig. 6a). In order to investigate the effect of heat-inactivation in vivo, mice 
were immunized twice with TLA and TLA H and TLA-specific humoral and cellular responses between both 
groups (TLA and TLA H) were compared (Fig. 6b,c). As shown in Fig. 6b, levels of TLA-specific antibodies 
on day 21 were comparable between both experimental groups. Stimulation of spleen cells of mice immunized 
with TLA or TLA H with native TLA led to comparable levels of IL-6, TNFα, IL-5, IL-4 and IL-10 (Fig. 6c). 
Interestingly, immunization with the heat-inactivated TLA led to an increased production of IFNγ in stimulated 
splenocytes compared to immunization with the native TLA.
Figure 2. Antibody production and recall responses in mice immunized with TLA. Mice were immunized 
intraperitoneally with 10 µg TLA in alum on days 0 and 10 (TLA group). Controls received PBS in alum (Sham 
group) (a). Levels of TLA-specific serum antibodies collected on day 0 and day 21 were determined by ELISA 
(b). Spleens were collected at day 21 and single cell suspensions (5 × 106 cells/ml) were cultured in the presence 
of medium only (Med) or 5 µg/ml TLA for 72 h. Levels of cytokines in culture supernatants were determined 
by ELISA (c). Data are representative of three experiments (n = 5 mice per group). Results of Student´s t test: 
*P < 0.05, **P < 0.01, ***P < 0.001.
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TLA loses its immunostimulatory potential upon deglycosylation. Our results suggest that pro-
teins are not the key players involved in the TLA-induced immunomodulation, therefore TLA was exposed to 
different biochemical treatments and tested in vitro. In order to confirm the hypothesis that not the proteins but 
rather carbohydrates are involved in the immunomodulation, TLA was treated with proteinase K (TLA-ProtK) 
to digest proteins into peptides or with sodium metaperiodate (TLA D), to modify glycan moieties. Sodium 
metaperiodate treatment leads to destruction of carbohydrate integrity through alteration of three-dimensional 
structures of the molecules34. By using a panel of nine biotinylated lectins in an ELISA assay, we could show that 
TLA contains wide range of carbohydrate moieties, which were removed by sodium metaperiodate treatment 
(Supplementary Fig. S5). TLA-ProtK, TLA D, as well as TLA and TLA H, were used for in vitro stimulation of 
BMDC, which were isolated from naïve BALB/c mice. Levels of cytokines IL-6, TNFα, and IL-12p70 did not 
differ between TLA, TLA H and TLA-ProtK and were significantly increased compared to medium levels. Levels 
of IL-10 were reduced in TLA-ProtK-stimulated cells in comparison to levels observed in cultures with native 
TLA. Interestingly, TLA D failed to stimulate cytokine production in BMDC, which indicates that glycan moieties 
might be responsible for the immunomodulatory effect of TLA (Fig. 7).
Discussion
Studies in both humans and animal models demonstrated that certain parasitic infections modulate the host 
immune responses, which is often associated with protection against allergic diseases6,8,35. For example, respira-
tory allergies are less frequent among individuals infected with the protozoan parasite T. gondii21,23. In experimen-
tal settings we have previously shown that T. gondii infection, as well as inactivated extract of T. gondii oocysts 
prevented the development of airway inflammation in a mouse model of birch pollen allergy24,26. Similarly, Fenoy 
et al. have shown that T. gondii infection reduced the airway inflammation in a mouse model of OVA-induced 
allergy25,36. In the present study we tested immunomodulatory properties of an extract derived from T. gondii 
tachyzoites, in vitro and in vivo in naïve mice and in OVA-allergy model.
Figure 3. Effect of TLA on the development of allergic airway inflammation. Mice were immunized 
intraperitoneally with 50 µg of TLA admixed to 10 µg of ovalbumin in alum (TLA + OVA/OVA group) on day 0 
and 14 and intranasal challenge with 100 µg of OVA was given at days 21–23. Control groups were immunized 
with 10 µg of ovalbumin in alum (OVA/OVA), 50 µg TLA in alum (TLA/PBS) and PBS in alum (PBS/PBS) and 
challenged with OVA or PBS (a). Airway hyperresponsiveness (AHR) was assessed in the response to inhalation 
of increasing doses of methacholine on day 24 (b). Number of differential cells in bronchoalveolar lavage (BALF) 
(c) and representative cytospins of BALF stained with haematoxylin and eosin (H&E; 100x magnification; arrow 
indicates eosinophil) (d). Representative lung tissue sections stained with H&E and Periodic Acid Schiff (PAS; 40x 
magnification; scale bars, 100 µm) (e). Mean gross lung histopathology score (f). Data are representative of three 
experiments (n = 5 mice per group). Results of ANOVA test: *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 4. Effect of TLA on the production of cytokines in lungs. Mice were treated as indicated in Fig. 3a. 
Lungs were collected on day 25 and single cell suspensions (5 × 106 cells/ml) were cultured in the presence of 
medium (Med) or 50 µg/ml OVA for 72 h. Levels of cytokines in culture supernatants were assessed by ELISA. 
Data are representative of three experiments (n = 5 mice per group). Results of ANOVA test: ***P < 0.001.
Figure 5. Effect of TLA on the development of systemic immune responses. Mice were treated as indicated in 
Fig. 3a. Serum and spleens were collected on day 25. Levels of OVA-specific IgG2a and IgG1 were determined 
by ELISA. Degranulation of rat basophil leukaemia cells (RBL) by cross-linking of the FceRI-bound IgE with 
allergen (0.3 µg/ml OVA) was measured by the production of β-hexosaminidase (a). Levels of cytokines in 
supernatants from spleen cells cultured with media only (Med) or 50 µg/ml OVA for 72 h was measured by 
ELISA (b). Data are representative of three experiments (n = 5 mice per group). Results of ANOVA test: 
*P < 0.05, **P < 0.01, ***P < 0.001.
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Although the immune response to acute infection with T. gondii in humans and mice is shifted towards Th1 
type, which is mandatory to control parasite replication24,37,38, we observed that immunization of mice by i.p. 
injection of TLA in alum induced mixed Th1/Th2 humoral and cellular immune responses. We detected substan-
tial levels of T. gondii-specific serum IgG2a, a Th1-associated isotype as well as IgG1, a Th2-associated isotype, in 
samples collected after two immunizations at sacrifice. Similarly, high levels of both Th1 and Th2 cytokines, such 
as IFNγ and TNFα, or IL-4 and IL-5, respectively, were detected in TLA-stimulated splenocytes. These results are 
in agreement with our previous findings, as well as with the study by Costa-Silva et al., who described that immu-
nization of mice with T. gondii-derived products induced mixed humoral and cellular Th1 and Th2 responses39,40.
Furthermore, we could show that TLA application in combination with allergic sensitization and challenge 
suppressed allergic immune response to OVA, demonstrated by reduced airway hyperresponsivness, reduced 
influx of eosinophils, peribronchial and perivascular infiltration of inflammatory cells, as well as Th2 cytokines in 
lungs compared to sensitized controls. In parallel, levels of Th2 cytokines in OVA-restimulated splenocytes as well 
as Th2-associated specific serum antibody IgG1 were reduced in TLA-treated mice in comparison to sham-treated 
sensitized controls. The potential of TLA to reduce Th2 responses has been documented by Liesenfeld et al. in 
a mouse model of infection with Nippostrongylus brasiliensis37. The authors showed that administration of TLA 
prior to N. brasiliensis infection reduced levels of total IgE in serum and numbers of eosinophils in the periphery. 
However, the suppressive effect on Th2 responses was short-lived. The experimental setup in our study does not 
allow us to investigate whether the anti-allergic effects of TLA are long-lasting, therefore, follow-up experiments 
will focus on this aspect.
Figure 6. Impact of heat-treatment on the immunomodulatory properties of TLA. Splenocytes of naïve 
mice were cultured with 5 µg of native TLA (TLA) or heat-inactivated TLA (TLA H) for 72 h (a). Mice were 
immunized intraperitoneally with 10 µg TLA in alum (TLA group) or 10 µg of heat-inactivated TLA (TLA 
H group) on days 0 and 10. Controls received PBS in alum (Sham group). Serum and spleens were collected 
on day 21. TLA-specific IgG2a and IgG1 in serum were assessed by ELISA (b). Spleen cell cultures were 
restimulated with 5 µg/ml TLA or with medium only (Med) and incubated for 72 h. Levels of cytokines in 
culture supernatants were determined by ELISA (c). Data are representative of three experiments (n = 5 mice 
per group). Results of ANOVA test: *P < 0.05, **P < 0.01, ***P < 0.001.
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Here we have shown that TLA-treatment led to increased levels of IFNγ in OVA-restimulated lung and spleen 
cell cultures. Similar effect was observed previously in allergic mice with T. gondii infection24,36. Although high levels 
of IFNγ has been associated with exacerbated symptoms of asthma in humans and mice41, the importance of this 
cytokine in allergy prevention was demonstrated for example in the study by Brand et al. who could show that the 
farm-derived bacterial strain Acinetobacter Iwoffii F78, prevented the development of allergy in IFNγ-dependent 
manner42. Also, induction of IFNγ has proven to be crucial in the prevention of house dust mite allergy43.
On the other hand, a regulatory cytokine IL-10 has been shown to play an important role in parasite-induced 
suppression of allergy44–46. TLA induced high levels of IL-10 in vitro in spleen cell cultures derived from naïve or 
TLA-immunized mice and in cultures with BMDC. However, in TLA-treated allergic mice this cytokine was not 
detectable in OVA-stimulated lung and spleen cell cultures. This suggests that IL-10 is not a key cytokine involved 
in TLA-induced allergy prevention and this is in agreement with findings by Fenoy et al., who could show that T. 
gondii-induced suppression of allergy is IL-10-independent47. We have previously shown that decreased levels of 
antigen-specific IL-10 in cell cultures could be explained by increased uptake via upregulated IL-10 receptor48. 
However, the cellular source of IFNγ and its role, as well as the exact role of IL-10 in allergy-suppression by TLA 
still remains to be investigated.
In order to investigate the nature of molecules responsible for immunomodulatory effects, TLA was 
heat-inactivated or treated with proteinase K to elucidate the relevance of proteins, or treated with sodium meta-
periodate to clarify the role of glycans. We have demonstrated that deglycosylated TLA failed to induce IL-6, 
TNFα, IL-10 or IL-12p70 production in stimulated dendritic cells, whereas interference with protein activities 
did not influence stimulatory properties of TLA, suggesting that heat-stable carbohydrates might play an impor-
tant role in parasite-host interaction and immunomodulatory effect of TLA.
Parasite-derived glycans have been shown to play an important role in immunomodulation. For example, 
glycoconjugates from Trichuris suis, Fasciola hepatica or the major immunogenic glycan element of schistosomes, 
Lewisx, have been shown to induce activation of antigen-presenting cells and participate in modulation of host 
immunity by interacting with C-type lectins49–51. Of interest, it has been shown that glycosylation is a com-
mon modification of T. gondii proteins52. In tachyzoites, enzymes involved in O-glycosylation are constitutively 
Figure 7. In vitro stimulation of bone marrow-derived dendritic cells with heat-inactivated, proteinase 
K-treated and deglycosylated TLA. Bone marrow-derived dendritic cells (BMDC) were cultured with media 
only (Med), 5 µg/ml TLA (TLA), heat-inactivated TLA (TLA H), TLA digested with proteinase K (TLA-ProtK), 
or deglycosylated TLA (TLA D), and LPS (1 µg/ml) for 24 h. Levels of cytokines in culture supernatants were 
determined by ELISA. All data are representative of at least two independent experiments. Results of Student´s t 
test: *P < 0.05, **P < 0.01, ***P < 0.001.
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expressed and novel O-linked glycosylated proteins have been identified53. Also the presence of N-glycosylation 
pathway in tachyzoites of T. gondii has been demonstrated and it has been shown that several key proteins 
involved in invasion and motility are N-linked glycoproteins30,54. Our data indicate that glycans of T. gondii 
tachyzoites have a role in the immunomodulation and studies on detailed characterization of the glycosylation 
pattern of TLA are in progress.
Taken together, we could show that TLA exhibits strong immunostimulatory properties in vitro and in 
vivo, inducing mixed Th1/Th2 profile in BALB/c mice. Furthermore, co-application of TLA with the allergen 
reduced allergic sensitization and airway inflammation in a mouse model of OVA allergy. The fact that the immu-
nostimulatory potential of TLA is lost upon deglycosylation indicates that its immunomodulatory effects are 
glycan-mediated. Our findings contribute to the understanding of host-parasite interactions and may pave the 
way for the design of novel well-tolerated immunotherapies for human immune-mediated disorders.
Materials and Methods
Animals. Female BALB/c mice aged 6–8 weeks were purchased from Charles River (Sulzfeld, DE) and 
kept under conventional housing conditions. All experiments were approved by the Animal Experimentation 
Committee of Medical University of Vienna and the Austrian Federal Ministry of Education, Science and Culture 
and all methods were performed according to their guidelines and regulations.
Parasites. T. gondii tachyzoites (strain S-48) were cultured in Vero cells (ATCC Number CCL-81, LGC 
Standards GmbH, DE) for 4 days in RPMI-1640 medium (Sigma-Aldrich, USA) supplemented with 4% FBS 
(HyClone®, GE Healthcare, UK) and 1% L-Glutamine-Pen/Strep × 100 (Sigma-Aldrich) under 5% CO2 and 
at 37 °C. Tachyzoites were purified from Vero cells by discontinuous Percoll® (GE Healthcare Biosciences AB, 
SE) density gradient centrifugation (9,000 × g, 15 min) and resuspended in PBS. Counting was performed in a 
Bürker-Türk-chamber (Hecht-Assistent®, DE) and 2 × 109 T. gondii tachyzoites per ml PBS were stored at −80 °C.
Preparation of TLA. TLA was prepared by three freeze-thaw cycles in liquid nitrogen, followed by soni-
cation (10 × 30 s at 2 min intervals at 4 °C) in the presence of protease inhibitors (Complete® Protease Inhibitor 
Cocktail tablets; Roche, DE) and subsequently centrifuged at 10,000 × g (60 min at 4 °C). Supernatant was col-
lected, sterile filtered (22 µm Millex®GV Filter Unit, Merck Milipore, IRL) and protein concentration was meas-
ured with a BCA Protein Assay Reagent kit (Pierce Peribo, USA). Endotoxin levels in TLA were determined by 
Limulus Amoebocyte Lysate (LAL) (Endpoint Chromogenic LAL Assay; Lonza LTD, CH) and they were below 
0.1 EU in 1 µg of extract. TLA was stored at −80 °C until use.
Heat-inactivation, proteinase K and periodate treatment. Heat-inactivation of TLA was achieved 
by incubation at 96 °C for 15 min (TLA H). Furthermore, TLA was enzymatically treated with 1 mg/ml proteinase 
K (QIAGEN GmbH, DE) at 37 °C overnight, followed by 20 min incubation at 96 °C in order to inactivate the 
enzyme (TLA-ProtK). Sodium metaperiodate-mediated modification of glycan moieties in TLA (TLA D) was 
performed as follows. 450 µg TLA was treated with 50 µl 100 mM sodium metaperiodate (Sigma-Aldrich) to yield 
final concentration of 10 mM, at pH 4.5 for 45 min at room temperature (RT) in the dark. The oxidation reaction 
was stopped with 100 µl of sodium borohydride (Merck) at a final concentration of 50 mM, at pH 4.5 for 30 min 
at RT in the dark. Excess salt was removed by exchanging reaction buffer with PBS by using desalting columns 
(Zeba Spin Desalting Columns, 7 K MWCO, Pierce Biotechnology, Thermoscientific, USA) and the protein con-
centration was assessed as above.
Stimulation of splenocytes and dendritic cells. Single cell suspensions were prepared from spleens of 
naïve BALB/c mice and resuspended in complete media (RPMI-1640 supplemented with 10% heat-inactivated 
FCS, 2 mM L-glutamine, 2 mM mercaptoethanol, 100 µg/ml gentamicin; Sigma-Aldrich). Cells (5 × 106/ml) 
were incubated with 10 and 5 µg/ml TLA, 5 µg/ml TLA H, synthetic triacylated lipopeptide (Pam3CSK; 1 µg/ml; 
Invivogen, USA) and ultra-pure lipopolysaccharide from E. coli (LPS; 1 µg/ml; Invivogen) for 72 h.
Bone marrow precursor cells were isolated from murine femurs and tibias of naïve female BALB/c mice and 
cultured in complete media supplemented with GM-CSF (20 ng/ml; Peprotech, USA) as described previously16. 
On day 8, bone marrow-derived dendritic cells (BMDC) (1 × 106/ml) were incubated with media only, 5 µg/ml 
TLA, TLA H, TLA-ProtK, TLA D or LPS (1 µg/ml) for 24 h. Both splenocytes and BMDC cultures were kept in 
the incubator at 37 °C and 5% CO2. Supernatants were collected and kept at −20 °C until further use. Detection 
of cytokines IL-6, IL-10, IL-12p70, IFNγ and TNFα in supernatants was performed by ELISA (Ready-Set-Go Kit, 
eBioscience, USA) according to the manufacturer´s instructions.
Immunization with TLA and heat-inactivated TLA. Mice were immunized intraperitoneally with 10 µg 
TLA in 140 µl alum (Alu-Gel-S Suspension, Serva Electrophoresis, DE) (TLA group), 10 µg heat-inactivated TLA 
in alum (TLA H group) or sham treated with PBS in alum (Sham group) on days 0 and 10. Blood samples were 
collected one day before the first immunization (day −1) and at the end of the experiment (day 21). Serum 
obtained after blood coagulation and centrifugation for 10 min at 1,500 × g was stored at −20 °C for further anal-
ysis. Levels of TLA-specific IgG1 and IgG2a antibodies were measured by ELISA. Briefly, microtiter plates (Nunc, 
DK) were coated with 4 µg/ml of TLA in coating buffer (0.1 M carbonate-bicarbonate buffer, pH 8.4) overnight 
at 4 °C. Coated plates were incubated with blocking buffer (PBS/0.05%Tween/1% BSA) for 6 h at RT. Plates were 
washed and incubated with diluted serum samples overnight at 4 °C. Sera were diluted 1:1000 for IgG1, 1:500 
for IgG2a and 1:10 for IgE. On the following day, plates were washed and incubated with rat-anti-mouse IgG1, 
IgG2a and IgE (1:500; Pharmingen, USA) for 6 h at RT. Plates were washed and incubated with horseradish 
peroxidase-conjugated mouse-anti-rat IgG (1:2000; Jackson ImmunoResearch Laboratories Inc., USA) for 1 h 
at 37 °C and then 1 h at 4 °C. Plates were washed, incubated with chromogenic substrate (1 mM ABTS in 70 mM 
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citric-phosphate buffer, pH 4.2; Sigma-Aldrich). Absorbance was measured at 405 nm on SparkControl Magellan 
plate reader (Tecan GmbH, AT). At sacrifice (d 21), spleens were collected and single cell suspensions were pre-
pared and cultured (5 × 106/ml) with 5 µg/ml TLA or media alone at 37 °C for 72 h. Supernatants were collected 
and levels of cytokines measured by ELISA as indicated above.
Mouse model of OVA-induced airway inflammation. Mice were immunized intraperitoneally with 
the mixture of 50 µg TLA and 10 µg OVA (grade V; Sigma-Aldrich) in 90 µl alum on days 0 and 14; and then 
challenged three times intranasally with 100 µg OVA in a final volume of 30 µl on days 21–23 (TLA + OVA/
OVA group). Before each challenge, mice were anesthetized by 5% isoflurane (Isocare; 100% w/v; Inhalation 
vapour, Animalcare Ltd, UK) in UniVet Porta anaesthesia machine (Groppler Medizintechnik, DE) with the 
airflow set at 3 L/min. Control groups were sensitized with 10 µg OVA and challenged with OVA (OVA/OVA 
group); treated with 50 µg TLA and challenged with 30 µl PBS (TLA/PBS group) or sham treated with PBS and 
challenged with PBS (PBS/PBS group). Mice were terminally anesthetized and organs were excised on day 25. In 
order to prepare single cell suspension, spleens were forced through a cell strainer and hemolyzed for 1 min in 
3 ml hemolysis buffer (150 mM ammonium chloride, 10 mM potassium bicarbonate and 0.1 mM EDTA). Lung 
cell isolation was performed as previously described55. Briefly, lungs were excised and minced in 6 ml serum-free 
RPMI-1640 media containing Liberase TL (0.5 mg/ml; Roche, DE) and DNase I (0.5 mg/ml; Sigma-Aldrich), 
incubated for 45 min at 37 °C and finally, the remaining tissue was forced through a 70 µm cell strainer (Falcon, 
Corning Inc., USA). Spleen and lung single cell cultures (5 × 106/ml) were restimulated with media and 50 µg/
ml endotoxin-free OVA (EndoGrade Ovalbumin, Hyglos GmbH, DE) for 72 h. Supernatants were collected and 
cytokines were measured by ELISA as described above. Levels of OVA-specific IgG1 and IgG2a were measured 
by ELISA. Microtiter plates were coated with 5 µg/ml OVA in coating buffer and ELISA was carried out as above.
Rat basophil leukaemia cell-based assay. Rat basophil leukaemia (RBL) cell mediator release assay was 
performed as previously described56. Briefly, RBL-2H3 (4 × 105/ml) cells were incubated with diluted sera (1:300) 
and degranulation was induced by adding 0.3 µg/ml OVA (grade V; Sigma-Aldrich) in Tyrode´s buffer (134 mM 
NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM HEPES, pH 7.4; Sigma-Aldrich). 
Fluorescence was measured at λex:360 nm/λem:465 nm using a fluorescence plate reader. Results represent the 
percentage of total ß-hexosaminidase release after addition of 1% Triton X-100.
Assessment of airway hyperresponsiveness. Airway hyperresponsiveness (AHR) was measured 
24 h after the last intranasal challenge by whole body plethysmography (DSI, Buxco Electronics Inc., USA) in 
conscious unrestrained animals in response to increasing doses (0–25 mg/ml) of aerosolized methacholine 
(acetyl-β-methyl-choline chloride, Sigma-Aldrich). The baseline was established in response to PBS inhalation, 
and airway resistance was determined by calculating dimensionless parameter enhanced pause (PenH) as previ-
ously described57.
Differential cell counts in bronchoalveolar lavage fluid. Lungs were lavaged with 2 × 1 ml PBS 
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4; pH 7.4) and collected bronchoalveolar 
lavage fluid (BALF) was centrifuged at 300 × g for 5 min at 4 °C. For differential cell counts, the cell pellet was 
resuspended and spun onto microscopic slides at 800 × g for 3 min (4 × 104 cells; Shandon Cytospin®, Shandon 
Southern Instruments, UK), air-dried and subsequently stained with haematoxylin and eosin (H&E; Hemacolor®, 
Merck, DE). Altogether, 200 macrophages, lymphocytes, eosinophils and neutrophils cells per slide were counted 
under the light microscope (Nikon Eclipse; 100x magnification).
Lung histology. Excised lung tissue was fixed with 7.5% formaldehyde-PBS and paraffin-embedded. 5 µm 
tick sections were stained with H&E and periodic acid-Schiff (PAS) stain. Histological pathology score was eval-
uated using light microscopy according to the method adapted from Zaiss et al.58: (i) perivascular and peri-
bronchiolar inflammation (grade: 0 = no changes; 1 = few perivascular and peribronchiolar inflammatory cells; 
2 = moderate numbers of cell cuffs on several perivascular and peribronchiolar sites; 3 = large number of diffuse 
infiltrated cell cuffs), (ii) presence of leukocytes in alveolar spaces (grade: 0 = no cells; 1 = 2–4 cells; 3 = 4 – 10 
cells; 3 = more than 10 cells), and (iii) number of PAS positive cells per 50 counted bronchoalveolar epithelial cells 
(0 = no cells; 1 = <12; 2 = 12–25; 3 =  > 25). The histopathological score is expressed as a sum of single scores.
Statistical analysis. Data were statistically analyzed by GraphPad Prism software (Graph Pad Software, 
USA) utilizing unpaired Student’s t-test and two-way ANOVA. All data are shown as mean ± standard error of 
the mean (SEM) and differences were considered significant at p < 0.05.
References
 1. Platts-Mills, T. A. The allergy epidemics: 1870–2010. J Allergy Clin Immunol 136, 3–13, https://doi.org/10.1016/j.jaci.2015.03.048 
(2015).
 2. Maizels, R. M. et al. Helminth parasites–masters of regulation. Immunol Rev 201, 89–116, https://doi.org/10.1111/j.0105-
2896.2004.00191.x (2004).
 3. Maizels, R. M. Parasite immunomodulation and polymorphisms of the immune system. J Biol 8, 62, https://doi.org/10.1186/jbiol166 
(2009).
 4. Fogarty, A. W. What have studies of non-industrialized countries told us about the cause of allergic disease? Clin Exp Allergy 45, 
87–93, https://doi.org/10.1111/cea.12339 (2015).
 5. Strachan, D. P. Hay fever, hygiene, and household size. BMJ 299, 1259–1260 (1989).
 6. Wilson, M. S. et al. Suppression of allergic airway inflammation by helminth-induced regulatory T cells. J Exp Med 202, 1199–1212, 
https://doi.org/10.1084/jem.20042572 (2005).
www.nature.com/scientificreports/
1 1ScIentIfIc REPoRTS | 7: 15211  | DOI:10.1038/s41598-017-15663-4
 7. Dittrich, A. M. et al. Helminth infection with Litomosoides sigmodontis induces regulatory T cells and inhibits allergic sensitization, 
airway inflammation, and hyperreactivity in a murine asthma model. J Immunol 180, 1792–1799 (2008).
 8. Aranzamendi, C. et al. Protection against allergic airway inflammation during the chronic and acute phases of Trichinella spiralis 
infection. Clin Exp Allergy 43, 103–115, https://doi.org/10.1111/cea.12042 (2013).
 9. Broadhurst, M. J. et al. IL-22 + CD4 + T cells are associated with therapeutic trichuris trichiura infection in an ulcerative colitis 
patient. Sci Transl Med 2, 60ra88, https://doi.org/10.1126/scitranslmed.3001500 (2010).
 10. Croese, J. et al. A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors. Gut 55, 136–137, 
https://doi.org/10.1136/gut.2005.079129 (2006).
 11. Croese, J. et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J Allergy Clin 
Immunol 135, 508–516, https://doi.org/10.1016/j.jaci.2014.07.022 (2015).
 12. Summers, R. W. et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128, 825–832 
(2005).
 13. Fleming, J. O. Helminths and multiple sclerosis: will old friends give us new treatments for MS? J Neuroimmunol 233, 3–5, https://
doi.org/10.1016/j.jneuroim.2011.01.003 (2011).
 14. Feary, J. R. et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy 40, 299–306, 
https://doi.org/10.1111/j.1365-2222.2009.03433.x (2010).
 15. McSorley, H. J. et al. Suppression of type 2 immunity and allergic airway inflammation by secreted products of the helminth 
Heligmosomoides polygyrus. Eur J Immunol 42, 2667–2682, https://doi.org/10.1002/eji.201142161 (2012).
 16. Schabussova, I. et al. Oesophagostomum dentatum extract modulates T cell-dependent immune responses to bystander antigens 
and prevents the development of allergy in mice. PLoS One 8, e67544, https://doi.org/10.1371/journal.pone.0067544 (2013).
 17. Hill, D. E., Chirukandoth, S. & Dubey, J. P. Biology and epidemiology of Toxoplasma gondii in man and animals. Anim Health Res 
Rev 6, 41–61 (2005).
 18. Hill, D. & Dubey, J. P. Toxoplasma gondii: transmission, diagnosis and prevention. Clinical Microbiology and Infection 8, 634–640, 
https://doi.org/10.1046/j.1469-0691.2002.00485.x (2002).
 19. Kim, K. & Weiss, L. M. Toxoplasma: the next 100years. Microbes Infect 10, 978–984, https://doi.org/10.1016/j.micinf.2008.07.015 
(2008).
 20. Robert-Gangneux, F. & Darde, M. L. Epidemiology of and diagnostic strategies for toxoplasmosis. Clin Microbiol Rev 25, 264–296, 
https://doi.org/10.1128/CMR.05013-11 (2012).
 21. Matricardi, P. M. et al. Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: 
epidemiological study. BMJ 320, 412–417 (2000).
 22. Matricardi, P. M., Rosmini, F., Panetta, V., Ferrigno, L. & Bonini, S. Hay fever and asthma in relation to markers of infection in the 
United States. J Allergy Clin Immunol 110, 381–387 (2002).
 23. Janse, J. J. et al. The association between foodborne and orofecal pathogens and allergic sensitisation–EuroPrevall study. Pediatr 
Allergy Immunol 25, 250–256, https://doi.org/10.1111/pai.12175 (2014).
 24. Wagner, A. et al. Immunoregulation by Toxoplasma gondii infection prevents allergic immune responses in mice. Int J Parasitol 39, 
465–472, https://doi.org/10.1016/j.ijpara.2008.09.003 (2009).
 25. Fenoy, I. et al. Toxoplasma gondii infection blocks the development of allergic airway inflammation in BALB/c mice. Clin Exp 
Immunol 155, 275–284, https://doi.org/10.1111/j.1365-2249.2008.03813.x (2009).
 26. Wagner, A. et al. Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch 
Pollen Allergy. PLoS One 11, e0155081, https://doi.org/10.1371/journal.pone.0155081 (2016).
 27. Hughes, H. P., Hudson, L. & Fleck, D. G. In vitro culture of Toxoplasma gondii in primary and established cell lines. Int J Parasitol 
16, 317–322 (1986).
 28. Ashburn, D., Evans, R., Chatterton, J. M., Joss, A. W. & Ho-Yen, D. O. Toxoplasma dye test using cell culture derived tachyzoites. J 
Clin Pathol 53, 630–633 (2000).
 29. da Costa-Silva, T. A., da S Meira, C., Frazzatti-Gallina, N. & Pereira-Chioccola, V. L. Toxoplasma gondii antigens: recovery analysis 
of tachyzoites cultivated in Vero cell maintained in serum free medium. Exp Parasitol 130, 463–469, https://doi.org/10.1016/j.
exppara.2012.01.005 (2012).
 30. Fauquenoy, S. et al. Proteomics and glycomics analyses of N-glycosylated structures involved in Toxoplasma gondii–host cell 
interactions. Mol Cell Proteomics 7, 891–910, https://doi.org/10.1074/mcp.M700391-MCP200 (2008).
 31. Fritz, H. M., Bowyer, P. W., Bogyo, M., Conrad, P. A. & Boothroyd, J. C. Proteomic analysis of fractionated Toxoplasma oocysts 
reveals clues to their environmental resistance. PLoS One 7, e29955, https://doi.org/10.1371/journal.pone.0029955 (2012).
 32. Possenti, A. et al. Global proteomic analysis of the oocyst/sporozoite of Toxoplasma gondii reveals commitment to a host-
independent lifestyle. BMC Genomics 14, 183, https://doi.org/10.1186/1471-2164-14-183 (2013).
 33. Sumino, K. et al. Methacholine challenge test: diagnostic characteristics in asthmatic patients receiving controller medications. J 
Allergy Clin Immunol 130, 69–75 e66, https://doi.org/10.1016/j.jaci.2012.02.025 (2012).
 34. Dell, A., Haslam, S. M., Morris, H. R. & Khoo, K. H. Immunogenic glycoconjugates implicated in parasitic nematode diseases. 
Biochim Biophys Acta 1455, 353–362 (1999).
 35. Scrivener, S. et al. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: 
a nested case-control study. The Lancet 358, 1493–1499, https://doi.org/10.1016/s0140-6736(01)06579-5 (2001).
 36. Fenoy, I. M. et al. Toxoplasma gondii infection modulate systemic allergic immune response in BALB/c mice. Exp Parasitol 154, 
47–50, https://doi.org/10.1016/j.exppara.2015.04.001 (2015).
 37. Liesenfeld, O., Dunay, I. R. & Erb, K. J. Infection with Toxoplasma gondii reduces established and developing Th2 responses induced 
by Nippostrongylus brasiliensis infection. Infect Immun 72, 3812–3822, https://doi.org/10.1128/IAI.72.7.3812-3822.2004 (2004).
 38. Pifer, R. & Yarovinsky, F. Innate responses to Toxoplasma gondii in mice and humans. Trends Parasitol 27, 388–393, https://doi.
org/10.1016/j.pt.2011.03.009 (2011).
 39. Wagner, A. et al. Prime-boost vaccination with toxoplasma lysate antigen, but not with a mixture of recombinant protein antigens, 
leads to reduction of brain cyst formation in BALB/c mice. PLoS One 10, e0126334, https://doi.org/10.1371/journal.pone.0126334 
(2015).
 40. Costa-Silva, T. A., Borges, M. M., Galhardo, C. S. & Pereira-Chioccola, V. L. Immunization with excreted/secreted proteins in AS/n 
mice activating cellular and humoral response against Toxoplasma gondii infection. Acta Trop 124, 203–209, https://doi.
org/10.1016/j.actatropica.2012.08.013 (2012).
 41. Raundhal, M. et al. High IFN-gamma and low SLPI mark severe asthma in mice and humans. J Clin Invest 125, 3037–3050, https://
doi.org/10.1172/JCI80911 (2015).
 42. Brand, S. et al. Epigenetic regulation in murine offspring as a novel mechanism for transmaternal asthma protection induced by 
microbes. J Allergy Clin Immunol 128(618–625), e611–617, https://doi.org/10.1016/j.jaci.2011.04.035 (2011).
 43. Pulsawat, P. et al. Optimization of a Der p 2-based prophylactic DNA vaccine against house dust mite allergy. Immunol Lett 151, 
23–30, https://doi.org/10.1016/j.imlet.2013.01.013 (2013).
 44. Danilowicz-Luebert, E. et al. A nematode immunomodulator suppresses grass pollen-specific allergic responses by controlling 
excessive Th2 inflammation. Int J Parasitol 43, 201–210, https://doi.org/10.1016/j.ijpara.2012.10.014 (2013).
 45. Larson, D. et al. Chronic helminth infection reduces basophil responsiveness in an IL-10-dependent manner. J Immunol 188, 
4188–4199, https://doi.org/10.4049/jimmunol.1101859 (2012).
www.nature.com/scientificreports/
1 2ScIentIfIc REPoRTS | 7: 15211  | DOI:10.1038/s41598-017-15663-4
 46. Okano, M., Satoskar, A. R., Nishizaki, K. & Harn, D. A. Jr. Lacto-N-fucopentaose III found on Schistosoma mansoni egg antigens 
functions as adjuvant for proteins by inducing Th2-type response. J Immunol 167, 442–450 (2001).
 47. Fenoy, I. M. et al. Regulatory cells induced by acute toxoplasmosis prevent the development of allergic lung inflammation. 
Immunobiology 220, 641–648, https://doi.org/10.1016/j.imbio.2014.11.016 (2015).
 48. Winkler, B. et al. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula 
vulgaris venom, in a murine model of wasp venom allergy. Immunology 110, 376–385 (2003).
 49. Klaver, E. J. et al. Trichuris suis-induced modulation of human dendritic cell function is glycan-mediated. Int J Parasitol 43, 191–200, 
https://doi.org/10.1016/j.ijpara.2012.10.021 (2013).
 50. Rodriguez, E. et al. Glycans from Fasciola hepatica Modulate the Host Immune Response and TLR-Induced Maturation of Dendritic 
Cells. PLoS Negl Trop Dis 9, e0004234, https://doi.org/10.1371/journal.pntd.0004234 (2015).
 51. van Die, I. et al. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and 
recognizes the glycan antigen Lewis x. Glycobiology 13, 471–478, https://doi.org/10.1093/glycob/cwg052 (2003).
 52. Luo, Q. et al. Analysis of the glycoproteome of Toxoplasma gondii using lectin affinity chromatography and tandem mass 
spectrometry. Microbes Infect 13, 1199–1210, https://doi.org/10.1016/j.micinf.2011.08.013 (2011).
 53. Wang, K. et al. Identification of Novel O-Linked Glycosylated Toxoplasma Proteins by Vicia villosa Lectin Chromatography. PLoS 
One 11, e0150561, https://doi.org/10.1371/journal.pone.0150561 (2016).
 54. Fauquenoy, S. et al. Unusual N-glycan structures required for trafficking Toxoplasma gondii GAP50 to the inner membrane complex 
regulate host cell entry through parasite motility. Mol Cell Proteomics 10(M111), 008953, https://doi.org/10.1074/mcp.M111.008953 
(2011).
 55. Lajoie, S. et al. IL-21 receptor signalling partially mediates Th2-mediated allergic airway responses. Clin Exp Allergy 44, 976–985, 
https://doi.org/10.1111/cea.12341 (2014).
 56. Repa, A. et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine 
model of birch pollen allergy. Vaccine 22, 87–95 (2003).
 57. Chong, B. T., Agrawal, D. K., Romero, F. A. & Townley, R. G. Measurement of bronchoconstriction using whole-body 
plethysmograph: comparison of freely moving versus restrained guinea pigs. J Pharmacol Toxicol Methods 39, 163–168 (1998).
 58. Zaiss, M. M. et al. The Intestinal Microbiota Contributes to the Ability of Helminths to Modulate Allergic Inflammation. Immunity 
43, 998–1010, https://doi.org/10.1016/j.immuni.2015.09.012 (2015).
Acknowledgements
We gratefully acknowledge funding from the Austrian Science Fund SFB F46 and DK MCCA and from OeAD-
GmbH grants CZ 15/2015 and CZ 13/2016. We thank Katharina Ambroz, Onisa Ul-Haq, Karin Baier, Erika 
Garner-Spitzer, Joshua Tobias, Dejana Dejanovic and Shi Yan for invaluable assistance and helpful discussions, 
as well as Zoe Zambalos for assistance with graphical presentation. We would like to thank to Irma van Die for 
providing biotinylated lectins.
Author Contributions
Conceived and designed the experiments: M.D., I.S., A.J., U.W. Performed the experiments: M.D., P.S., C.Z., E.K. 
Analyzed the data: M.D., I.S., U.W. Contributed reagents/materials/analysis tools: M.D., A.W., P.S., C.Z., E.K., 
G.L., R.P., A.J., U.W., I.S. Read the manuscript: M.D., A.W., A.J., U.W., I.S.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-017-15663-4.
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
